Health Affairs December 23, 2019
Peter J. Pitts

When it comes to 21st-century drug development, is the Food and Drug Administration (FDA) an accelerator or anchor for medical innovation? If the former, how can it do even better? If the latter, how big of a sea change is required?

To address that question head on, the FDA held a November 7 hearing under the title, “Promoting Effective Drug Development Programs: Opportunities and Priorities for FDA’s Office of New Drugs.” The stated purpose of the open public meeting was to solicit specific, actionable policy suggestions for the review staff of the FDA’s Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND) regarding opportunities to promote effective drug development while maintaining the FDA’s regulatory standards for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Pharma
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
FDA approves Merck drug for rare lung disorder
Neuronetics wins FDA clearance for device to treat adolescents with depression
FDA Approves Roche’s Cobas Malaria Test, Designed to Screen for Malaria in Potential Blood Donors
Merck Drug for Heart and Lung Disorder Wins a First-in-Class FDA Approval

Share This Article